Abstract:

Objective   To investigate the effects of platelet glycoprotein IIb/IIIa inhibitor tirofiban on left ventricular remodeling and clinical outcomes in patients with acute myocardial infarction (AMI)who received primary percutaneous coronary intervention(PCI). Methods  Eighty-five AMI patients on admission in emergency room were to be selected and divided into groups of control group(primary PCI alone, n=40) and experimental group(receiving primary PCI and tirofiban therapy, n=45). We evaluated the left ventricular ejection fraction(LVEF), left ventricular end-diastolic volume index(LVEDVI), left ventricular end-systolic volume index(LVESVI) and left ventricular end-diastolic dimension(LVEDD) of each patient by echocardiography at the time of admission and the 28 day after the onset of the AMI. At the same time, we recorded the frequency of major adverse cardiovascular events(MACE) and complications such as bleeding. Results     Two groups on the effects of cardiac remodeling is not statistically significance at the 1 day, but it can be found there are significant differences in LVEF、LVEDVI、LVESVI and LVEDD in experimental group on the 28 day(P<0.05). And the MACE rates are significantly reduced in tirofiban group.But there is not discrepant in the rate of bleeding. Conclusion    Adjunctive therapy with tirofiban for patients with AMI who underwent emergency PCI significantly improves left ventricular function and clinical outcomes during both hospitalization and 28 days′follow-up.But the rate of bleeding complication is proportionable.

Key words:  Myocardial infarction, acute; Tirofiban; Left ventricular remodeling; Outcomes